Amgen Inc. $AMGN Shares Sold by Capital International Investors

Posted by Brian Himes on Jun 7th, 2026

Capital International Investors trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,186,270 shares of the medical research company’s stock after selling 1,006,725 shares during the period. Amgen makes up approximately 0.9% of Capital International Investors’ holdings, making the stock its 27th biggest holding. Capital International Investors’ holdings in Amgen were worth $5,952,965,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of AMGN. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares during the period. Schnieders Capital Management LLC. lifted its stake in shares of Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares during the period. Main Street Financial Solutions LLC lifted its stake in shares of Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after buying an additional 416 shares during the period. Finally, Ieq Capital LLC lifted its stake in shares of Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after buying an additional 2,611 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Up 1.2%

AMGN opened at $349.58 on Friday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a fifty day moving average of $341.35 and a two-hundred day moving average of $345.47. The stock has a market capitalization of $188.67 billion, a price-to-earnings ratio of 24.33, a PEG ratio of 3.51 and a beta of 0.42.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

AMGN has been the subject of several research reports. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Morgan Stanley set a $332.00 price objective on shares of Amgen in a research note on Friday, May 1st. Piper Sandler lowered their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Finally, Leerink Partners reiterated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $353.81.

Get Our Latest Report on Amgen

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.